Share This:
https://ntp.niehs.nih.gov/go/21031

TDMS Study 96003-03 Pathology Tables

NTP Experiment-Test: 96003-03               INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (a)                     Report: PEIRPT02
Study Type: 39 WEEKS                                          ALLYL BROMIDE                                       Date: 03/30/01
Route: GAVAGE                                                                                                     Time: 09:19:00

                                                          FINAL#1/MICE




       Facility:  BIORELIANCE

       Chemical CAS #:  106-95-6

       Lock Date:  10/18/00

       Cage Range:  All

       Reasons For Removal:    All

       Removal Date Range:     All

       Treatment Groups:       Include 008    VEHICLE CONTROL
                               Include 009    0.5     MG/KG
                               Include 010    1 MG/KG
                               Include 011    2 MG/KG
                               Include 012    4 MG/KG
                               Include 013    8 MG/KG
                               Include 001    VEHICLE CONTROL
                               Include 002    0.5     MG/KG
                               Include 003    1 MG/KG
                               Include 004    2 MG/KG
                               Include 005    4 MG/KG
                               Include 006    8 MG/KG























a  Number of animals examined microscopically at site and number of animals with lesion

                                                              Page   1


NTP Experiment-Test: 96003-03               INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (a)                     Report: PEIRPT02
Study Type: 39 WEEKS                                          ALLYL BROMIDE                                       Date: 03/30/01  
Route: GAVAGE                                                                                                     Time: 09:19:00  
____________________________________________________________________________________________________________________________________
                                                                                                                                    
         MICE:TGAC (FVB/N) HEMIZYGOUS FEMALE       VEHICLE      0.5          1 MG/KG      2 MG/KG      4 MG/KG      8 MG/KG         
                                                   CONTROL      MG/KG                                                               
____________________________________________________________________________________________________________________________________
                                                                                                                                    
DISPOSITION SUMMARY                                                                                                                 
                                                                                                                                    
  Animals Initially in Study                          15           15           15           15           15           15           
  Early Deaths                                                                                                                      
    Dosing Accident                                    2                                                                            
    Moribund Sacrifice                                 2            3            4            6            1            3           
    Natural Death                                      2            2            3            1            3                        
  Survivors                                                                                                                         
    Terminal Sacrifice                                 9           10            8            8           11           12           
                                                                                                                                    
  Animals Examined Microscopically                    15           15           15           15           15           15           
                                                                                                                                    
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 ALIMENTARY SYSTEM                                                                                                                  
                                                                                                                                    
   Liver                                              (15)         (15)         (15)         (15)         (14)         (15)         
      Leukemia Erythrocytic                                         1 (7%)                                                          
      Lymphoma Malignant                               2 (13%)      1 (7%)                    1 (7%)                                
   Salivary Glands                                                              (3)                                                 
      Duct, Carcinoma                                                            3 (100%)                                           
   Stomach, Forestomach                               (14)         (15)         (12)         (13)         (14)         (15)         
      Squamous Cell Papilloma                          5 (36%)      8 (53%)      4 (33%)      7 (54%)      5 (36%)      6 (40%)     
      Squamous Cell Papilloma, Multiple                3 (21%)      2 (13%)      2 (17%)                   2 (14%)      4 (27%)     
   Tooth                                              (2)          (3)          (6)          (7)          (3)          (3)          
      Odontogenic Tumor                                2 (100%)     3 (100%)     6 (100%)     6 (86%)      2 (67%)      3 (100%)    
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 CARDIOVASCULAR SYSTEM                                                                                                              
                                                                                                                                    
   Heart                                                           (1)                       (1)                                    
      Lymphoma Malignant                                            1 (100%)                                                        
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 ENDOCRINE SYSTEM                                                                                                                   
                                                                                                                                    
   Adrenal Cortex                                     (13)         (14)         (12)         (13)         (12)         (15)         
      Lymphoma Malignant                                            1 (7%)                                                          
   Adrenal Medulla                                    (13)         (14)         (12)         (12)         (12)         (15)         
      Lymphoma Malignant                                            1 (7%)                                                          
   Pituitary Gland                                    (11)         (14)         (14)         (13)         (14)         (14)         
      Lymphoma Malignant                                                                      1 (8%)                                
____________________________________________________________________________________________________________________________________
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                             Page   2                                                               
                                                                                                                                   
NTP Experiment-Test: 96003-03               INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (a)                     Report: PEIRPT02
Study Type: 39 WEEKS                                          ALLYL BROMIDE                                       Date: 03/30/01  
Route: GAVAGE                                                                                                     Time: 09:19:00  
____________________________________________________________________________________________________________________________________
                                                                                                                                    
         MICE:TGAC (FVB/N) HEMIZYGOUS FEMALE       VEHICLE      0.5          1 MG/KG      2 MG/KG      4 MG/KG      8 MG/KG         
                                                   CONTROL      MG/KG                                                               
____________________________________________________________________________________________________________________________________
                                                                                                                                    
                                                                                                                                    
 GENERAL BODY SYSTEM                                                                                                                
                                                                                                                                    
   None                                                                                                                             
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 GENITAL SYSTEM                                                                                                                     
                                                                                                                                    
   Ovary                                              (13)         (15)         (14)         (14)         (13)         (15)         
      Lymphoma Malignant                               1 (8%)       1 (7%)                                                          
   Uterus                                             (13)         (15)         (13)         (14)         (12)         (15)         
      Lymphoma Malignant                                            1 (7%)                                                          
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 HEMATOPOIETIC SYSTEM                                                                                                               
                                                                                                                                    
   Lymph Node, Mesenteric                             (13)         (14)         (12)         (15)         (12)         (15)         
      Lymphoma Malignant                                            1 (7%)                                                          
   Lymph Node, Mediastinal                            (14)         (15)         (14)         (14)         (12)         (14)         
      Lymphoma Malignant                                            1 (7%)                                                          
   Spleen                                             (15)         (14)         (15)         (15)         (13)         (15)         
      Leukemia Erythrocytic                                         1 (7%)                                                          
      Lymphoma Malignant                               2 (13%)      1 (7%)                    1 (7%)                                
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 INTEGUMENTARY SYSTEM                                                                                                               
                                                                                                                                    
   Skin                                               (15)         (15)         (15)         (15)         (14)         (15)         
      Squamous Cell Papilloma                          1 (7%)       1 (7%)       3 (20%)      3 (20%)      5 (36%)      1 (7%)      
      Squamous Cell Papilloma, Multiple                                                                    1 (7%)                   
      Dermis, Fibrosarcoma                                                                                              1 (7%)      
      Lip, Squamous Cell Papilloma                     1 (7%)       1 (7%)                                 1 (7%)       3 (20%)     
      Vulva, Squamous Cell Papilloma                   2 (13%)      4 (27%)      1 (7%)       5 (33%)      4 (29%)      6 (40%)     
      Vulva, Squamous Cell Papilloma, Multiple                                                1 (7%)       1 (7%)       1 (7%)      
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 MUSCULOSKELETAL SYSTEM                                                                                                             
                                                                                                                                    
   None                                                                                                                             
____________________________________________________________________________________________________________________________________
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                             Page   3                                                               
                                                                                                                                   
NTP Experiment-Test: 96003-03               INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (a)                     Report: PEIRPT02
Study Type: 39 WEEKS                                          ALLYL BROMIDE                                       Date: 03/30/01  
Route: GAVAGE                                                                                                     Time: 09:19:00  
____________________________________________________________________________________________________________________________________
                                                                                                                                    
         MICE:TGAC (FVB/N) HEMIZYGOUS FEMALE       VEHICLE      0.5          1 MG/KG      2 MG/KG      4 MG/KG      8 MG/KG         
                                                   CONTROL      MG/KG                                                               
____________________________________________________________________________________________________________________________________
                                                                                                                                    
                                                                                                                                    
 NERVOUS SYSTEM                                                                                                                     
                                                                                                                                    
   None                                                                                                                             
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 RESPIRATORY SYSTEM                                                                                                                 
                                                                                                                                    
   Lung                                               (14)         (15)         (15)         (15)         (14)         (15)         
      Alveolar/Bronchiolar Adenoma                                                            2 (13%)                               
      Alveolar/Bronchiolar Carcinoma                                                                                    1 (7%)      
      Lymphoma Malignant                                            1 (7%)                    1 (7%)                                
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 SPECIAL SENSES SYSTEM                                                                                                              
                                                                                                                                    
   Harderian Gland                                                                                                     (1)          
      Adenoma                                                                                                           1 (100%)    
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 URINARY SYSTEM                                                                                                                     
                                                                                                                                    
   Kidney                                             (15)         (14)         (14)         (15)         (13)         (15)         
      Lymphoma Malignant                               1 (7%)       1 (7%)                    1 (7%)                                
                                                                                                                                    
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 SYSTEMIC LESIONS                                                                                                                   
                                                                                                                                    
   Multiple Organs                                   *(15)        *(15)        *(15)        *(15)        *(15)        *(15)         
      Leukemia Erythrocytic                                         1 (7%)                                                          
      Lymphoma Malignant                               2 (13%)      1 (7%)                    1 (7%)                                
____________________________________________________________________________________________________________________________________
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
     *   Number of animals with any tissue examined microscopically                                                                 
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                             Page   4                                                               
                                                                                                                                   
NTP Experiment-Test: 96003-03               INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (a)                     Report: PEIRPT02
Study Type: 39 WEEKS                                          ALLYL BROMIDE                                       Date: 03/30/01  
Route: GAVAGE                                                                                                     Time: 09:19:00  
____________________________________________________________________________________________________________________________________
                                                                                                                                    
         MICE:TGAC (FVB/N) HEMIZYGOUS FEMALE       VEHICLE      0.5          1 MG/KG      2 MG/KG      4 MG/KG      8 MG/KG         
                                                   CONTROL      MG/KG                                                               
____________________________________________________________________________________________________________________________________
                                                                                                                                    
TUMOR SUMMARY                                                                                                                       
                                                                                                                                    
   Total Animals with Primary Neoplasms (b)            10          13          10          14          11          14               
     Total Primary Neoplasms                           16          21          19          25          21          27               
                                                                                                                                    
   Total Animals with Benign Neoplasms                  9          10           8           9          11          14               
     Total Benign Neoplasms                            12          16          10          18          19          22               
                                                                                                                                    
   Total Animals with Malignant Neoplasms               2           2           3           1                       2               
     Total Malignant Neoplasms                          2           2           3           1                       2               
                                                                                                                                    
   Total Animals with Metastatic Neoplasms                                                                                          
     Total Metastatic Neoplasm                                                                                                      
                                                                                                                                    
   Total Animals with Malignant Neoplasms                                                                                           
   Uncertain Primary Site                                                                                                           
                                                                                                                                    
   Total Animals with Neoplasms Uncertain-                                                                                          
   Benign or Malignant                                  2           3           6           6           2           3               
     Total Uncertain Neoplasms                          2           3           6           6           2           3               
                                                                                                                                    
                                                                                                                                    
____________________________________________________________________________________________________________________________________
a  Number of animals examined microscopically at site and number of animals with lesion                                             
b  Primary tumors: all tumors except metastatic tumors                                                                              
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                             Page   5                                                               
                                                                                                                                   
NTP Experiment-Test: 96003-03               INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (a)                     Report: PEIRPT02
Study Type: 39 WEEKS                                          ALLYL BROMIDE                                       Date: 03/30/01  
Route: GAVAGE                                                                                                     Time: 09:19:00  
____________________________________________________________________________________________________________________________________
                                                                                                                                    
         MICE:TGAC (FVB/N) HEMIZYGOUS MALE         VEHICLE      0.5          1 MG/KG      2 MG/KG      4 MG/KG      8 MG/KG         
                                                   CONTROL      MG/KG                                                               
____________________________________________________________________________________________________________________________________
                                                                                                                                    
DISPOSITION SUMMARY                                                                                                                 
                                                                                                                                    
  Animals Initially in Study                          15           15           15           15           15           15           
  Early Deaths                                                                                                                      
    Moribund Sacrifice                                 2            2            3            2            4            1           
    Natural Death                                      1            3            3                         4            2           
    Dosing Accident                                                 1                         1            1            1           
  Survivors                                                                                                                         
    Terminal Sacrifice                                12            9            9           12            6           11           
                                                                                                                                    
  Animals Examined Microscopically                    15           15           15           15           15           15           
                                                                                                                                    
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 ALIMENTARY SYSTEM                                                                                                                  
                                                                                                                                    
   Liver                                              (14)         (15)         (14)         (15)         (14)         (15)         
      Leukemia Erythrocytic                                                      1 (7%)                    1 (7%)       1 (7%)      
   Salivary Glands                                                 (1)          (1)          (1)                                    
      Duct, Carcinoma                                               1 (100%)     1 (100%)     1 (100%)                              
   Stomach, Forestomach                               (15)         (14)         (14)         (15)         (13)         (14)         
      Squamous Cell Papilloma                          5 (33%)      3 (21%)      5 (36%)      5 (33%)      5 (38%)      5 (36%)     
      Squamous Cell Papilloma, Multiple                1 (7%)       2 (14%)      1 (7%)       1 (7%)                                
   Tooth                                              (5)          (5)          (4)          (3)          (6)          (4)          
      Odontogenic Tumor                                5 (100%)     5 (100%)     3 (75%)      3 (100%)     6 (100%)     3 (75%)     
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 CARDIOVASCULAR SYSTEM                                                                                                              
                                                                                                                                    
   None                                                                                                                             
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 ENDOCRINE SYSTEM                                                                                                                   
                                                                                                                                    
   None                                                                                                                             
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 GENERAL BODY SYSTEM                                                                                                                
                                                                                                                                    
   None                                                                                                                             
____________________________________________________________________________________________________________________________________
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                             Page   6                                                               
                                                                                                                                   
NTP Experiment-Test: 96003-03               INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (a)                     Report: PEIRPT02
Study Type: 39 WEEKS                                          ALLYL BROMIDE                                       Date: 03/30/01  
Route: GAVAGE                                                                                                     Time: 09:19:00  
____________________________________________________________________________________________________________________________________
                                                                                                                                    
         MICE:TGAC (FVB/N) HEMIZYGOUS MALE         VEHICLE      0.5          1 MG/KG      2 MG/KG      4 MG/KG      8 MG/KG         
                                                   CONTROL      MG/KG                                                               
____________________________________________________________________________________________________________________________________
                                                                                                                                    
                                                                                                                                    
 GENITAL SYSTEM                                                                                                                     
                                                                                                                                    
   None                                                                                                                             
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 HEMATOPOIETIC SYSTEM                                                                                                               
                                                                                                                                    
   Spleen                                             (15)         (14)         (14)         (15)         (14)         (15)         
      Leukemia Erythrocytic                                                      1 (7%)                    1 (7%)       1 (7%)      
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 INTEGUMENTARY SYSTEM                                                                                                               
                                                                                                                                    
   Skin                                               (15)         (15)         (15)         (15)         (14)         (15)         
      Keratoacanthoma                                                            3 (20%)                                            
      Squamous Cell Papilloma                          4 (27%)      1 (7%)       5 (33%)      2 (13%)      1 (7%)       1 (7%)      
      Squamous Cell Papilloma, Multiple                1 (7%)                    2 (13%)      1 (7%)       1 (7%)       3 (20%)     
      Conjunctiva, Squamous Cell Carcinoma                                                                 1 (7%)                   
      Lip, Squamous Cell Papilloma                                  1 (7%)       1 (7%)                                 1 (7%)      
      Lip, Squamous Cell Papilloma, Multiple           1 (7%)                                 1 (7%)                                
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 MUSCULOSKELETAL SYSTEM                                                                                                             
                                                                                                                                    
   None                                                                                                                             
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 NERVOUS SYSTEM                                                                                                                     
                                                                                                                                    
   None                                                                                                                             
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 RESPIRATORY SYSTEM                                                                                                                 
                                                                                                                                    
   Lung                                               (15)         (15)         (14)         (15)         (14)         (15)         
      Alveolar/Bronchiolar Adenoma                     1 (7%)                                 1 (7%)       2 (14%)                  
      Alveolar/Bronchiolar Carcinoma                                1 (7%)                                                          
      Carcinoma, Metastatic, Salivary Glands                                     1 (7%)                                             
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                             Page   7                                                               
                                                                                                                                   
NTP Experiment-Test: 96003-03               INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (a)                     Report: PEIRPT02
Study Type: 39 WEEKS                                          ALLYL BROMIDE                                       Date: 03/30/01  
Route: GAVAGE                                                                                                     Time: 09:19:00  
____________________________________________________________________________________________________________________________________
                                                                                                                                    
         MICE:TGAC (FVB/N) HEMIZYGOUS MALE         VEHICLE      0.5          1 MG/KG      2 MG/KG      4 MG/KG      8 MG/KG         
                                                   CONTROL      MG/KG                                                               
____________________________________________________________________________________________________________________________________
                                                                                                                                    
RESPIRATORY SYSTEM - cont                                                                                                           
      Leukemia Erythrocytic                                                      1 (7%)                                             
                                                                                                                                    
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 SPECIAL SENSES SYSTEM                                                                                                              
                                                                                                                                    
   None                                                                                                                             
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 URINARY SYSTEM                                                                                                                     
                                                                                                                                    
   None                                                                                                                             
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 SYSTEMIC LESIONS                                                                                                                   
                                                                                                                                    
   Multiple Organs                                   *(15)        *(15)        *(15)        *(15)        *(15)        *(15)         
      Leukemia Erythrocytic                                                      1 (7%)                    1 (7%)       1 (7%)      
____________________________________________________________________________________________________________________________________
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
     *   Number of animals with any tissue examined microscopically                                                                 
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                             Page   8                                                               
                                                                                                                                   
NTP Experiment-Test: 96003-03               INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (a)                     Report: PEIRPT02
Study Type: 39 WEEKS                                          ALLYL BROMIDE                                       Date: 03/30/01  
Route: GAVAGE                                                                                                     Time: 09:19:00  
____________________________________________________________________________________________________________________________________
                                                                                                                                    
         MICE:TGAC (FVB/N) HEMIZYGOUS MALE         VEHICLE      0.5          1 MG/KG      2 MG/KG      4 MG/KG      8 MG/KG         
                                                   CONTROL      MG/KG                                                               
____________________________________________________________________________________________________________________________________
                                                                                                                                    
TUMOR SUMMARY                                                                                                                       
                                                                                                                                    
   Total Animals with Primary Neoplasms (b)            11          10          11          11          12          10               
     Total Primary Neoplasms                           18          14          22          15          17          14               
                                                                                                                                    
   Total Animals with Benign Neoplasms                  9           5           9           9           8           7               
     Total Benign Neoplasms                            13           7          17          11           9          10               
                                                                                                                                    
   Total Animals with Malignant Neoplasms                           2           2           1           2           1               
     Total Malignant Neoplasms                                      2           2           1           2           1               
                                                                                                                                    
   Total Animals with Metastatic Neoplasms                                      1                                                   
     Total Metastatic Neoplasm                                                  1                                                   
                                                                                                                                    
   Total Animals with Malignant Neoplasms                                                                                           
   Uncertain Primary Site                                                                                                           
                                                                                                                                    
   Total Animals with Neoplasms Uncertain-                                                                                          
   Benign or Malignant                                  5           5           3           3           6           3               
     Total Uncertain Neoplasms                          5           5           3           3           6           3               
                                                                                                                                    
                                                                                                                                    
____________________________________________________________________________________________________________________________________
a  Number of animals examined microscopically at site and number of animals with lesion                                             
b  Primary tumors: all tumors except metastatic tumors                                                                              
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                             Page   9                                                               
                                                                                                                                   
                             ------------------------------------------------------------                                           
                             ----------              END OF REPORT             ----------                                           
                             ------------------------------------------------------------